Bioporto A/S epitomizes strong values and a robust corporate philosophy. As a leading biotech company, Bioporto A/S is dedicated to improving patient care and advancing the field of medical diagnostics. The company's core values revolve around innovation, integrity, and a commitment to excellence. By focusing on cutting-edge technologies and scientific advancements, Bioporto A/S aims to deliver reliable diagnostic solutions that empower healthcare professionals worldwide. With a passion for scientific excellence and a patient-centric approach, Bioporto A/S continually strives to make a positive impact on global healthcare, making it a trusted name in the biotech industry.

Bioporto A/S is primarily present in multiple countries and regions worldwide. Its extensive presence extends to North America, Europe, Asia, and Latin America. The company operates across a diverse range of markets, including the United States, Germany, China, Brazil, and many more. With its global reach, Bioporto A/S demonstrates its commitment to serving a wide range of customers and markets.

Bioporto A/S has achieved significant milestones in its growth and development. The company has successfully launched and commercialized innovative medical diagnostic products worldwide. It has received regulatory approvals and established partnerships to expand its product portfolio and market reach. Additionally, Bioporto A/S has shown promising results in clinical trials, solidifying its position as a leader in the industry. The company's relentless dedication to advancing healthcare through cutting-edge technology and strategic collaborations has paved the way for its continued success.

Bioporto A/S is a Denmark-based biotechnology company. Founded in 1988, Bioporto specializes in the development and commercialization of novel diagnostic tests for acute care settings. The company focuses on biomarker-based diagnostics that improve patient outcomes and guide clinical decision-making. Over the years, Bioporto has built a strong reputation for its commitment to innovation and high-quality products. It has established a global presence and collaborates with renowned research institutions and industry partners. Bioporto A/S continues to strive for advancements in diagnostic solutions, aiming to make a positive impact on healthcare delivery worldwide.

The main competitors of Bioporto A/S in the market include companies such as Siemens Healthineers, Roche Diagnostics, and Abbott Laboratories. These competitors also provide diagnostic solutions and medical devices that cater to similar areas as Bioporto A/S. However, Bioporto A/S differentiates itself through its pioneering product, The NGAL Test™, which enables early detection of acute kidney injury. Despite facing competition from well-established players, Bioporto A/S continues to uphold its strong market position through its innovative offerings and commitment to improving patient outcomes.

Bioporto A/S is primarily active in the biotechnology and healthcare industries.

Bioporto A/S, a leading biotechnology company, operates based on a robust business model focused on the development, production, and commercialization of innovative diagnostic products. The company specializes in the field of acute care diagnostics, providing healthcare professionals with advanced solutions to support accurate and timely diagnosis. Bioporto A/S aims to improve patient outcomes by offering diagnostic tests that help identify and monitor critical medical conditions. Their extensive product portfolio includes the well-renowned The NGAL Test™, which aids early detection of acute kidney injury. Through their diligent research, development, and commercialization efforts, Bioporto A/S continues to contribute significantly to the healthcare industry worldwide.

Det Bioporto A/S P/E-forhold er -19,45.

Bioporto A/S KUV er 18,46.

AlleAktien Kvalitetsscore for Bioporto A/S er 6/10.

Den forventede Bioporto A/S omsætning er 40,40 mio. DKK.

Den forventede Bioporto A/S indtjening er -38,35 mio. DKK.

Bioporto A/S is a Danish company that operates in the fields of diagnostics and research. The company focuses on developing diagnostic tests and instruments based on biomarkers to address some of the biggest challenges in medicine. The company has three main business areas: Diagnostic tests, instrumental diagnostics, and research & development. These areas are closely interconnected and contribute to the products and services offered by Bioporto A/S to its customers. The Diagnostic Tests area includes a range of test kits that can be used for diagnosing diseases such as heart failure, multiple sclerosis, and inflammatory bowel diseases. The company specializes in biomarker-based tests that enable doctors and clinics to make early and accurate diagnoses and improve patient treatment. An example of such a product is the NGAL test. NGAL is a biomarker released in kidney diseases, enabling early diagnosis. In the Instrumental Diagnostics area, Bioporto A/S offers a range of laboratory diagnostic devices that can be used in clinics and laboratories. These instruments are capable of quickly and accurately analyzing a wide range of clinical samples. An example of such an instrument is the NGAL Test System, specifically developed for the NGAL test in clinical laboratories. Bioporto A/S' Research & Development department focuses on identifying new biomarkers and developing new test procedures. The company follows an innovative approach based on its own research as well as collaborations with other universities and research institutions. This leads to the development of new diagnostic products and procedures. Bioporto A/S not only offers products to its customers but also comprehensive services such as training, support in implementing test procedures, and technical support. This allows customers to utilize Bioporto A/S products optimally and make their work more efficient. Overall, Bioporto A/S has a strong business model based on a solid scientific approach. The company is capable of developing precise and reliable diagnostic instruments and tests to meet the needs of doctors and clinics. Furthermore, Bioporto A/S is an important player in the research and development of biomarkers and diagnostic methods and is expected to continue playing a significant role in addressing some of the biggest medical challenges.

Bioporto A/S udbetaler et udbytte på 0 DKK fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Bioporto A/S, eller selskabet udbetaler ikke udbytte.

ISIN'en for Bioporto A/S er DK0011048619.

WKN for Bioporto A/S er 893191.

Tickeren for Bioporto A/S er BIOPOR.CO.

I løbet af de sidste 12 måneder betalte Bioporto A/S en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Bioporto A/S sandsynligvis betale en dividende på 0 DKK.

Udbytteafkastet for Bioporto A/S er i øjeblikket .

Bioporto A/S betaler kvartalsvis udbytte. Dette uddeles i månederne .

Bioporto A/S betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 DKK. Dette svarer til et dividendeafkast på 0 %.

Bioporto A/S bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Bioporto A/S fra den 10.7.2024 på 0 DKK, skulle du have haft aktien i din portefølje før ex-datoen den 10.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 10.7.2024.

I løbet af 2023 udbetalte Bioporto A/S 0 DKK i form af dividender.

Udbytterne fra Bioporto A/S udbetales i DKK.